Wakayama Medical University has submitted a patent (WO2013168829A1) (256) for a monoclonal antibody against OSMRβ designed to inhibit both OSM and IL-31 induced inflammation in patients with atopic dermatitis. This evidence concerns the gene IL31 and atopic eczema.